EXEL Exelixis Earnings and EPS analysis

?
Relative Growth: Rel. Growth: 95
Relative Strength: Rel. Strength: 74
Relative Valuation: Rel. Valuation: 68
Relative Profitability: Rel. Profitability: 98

EPS in 2026 (TTM): $3.12

Last Report Period Date: Mar 31, 2026

As of July 2026, according to Exelixis's latest financial report, the company's current EPS (TTM) is $3.12. In 2025, the company recorded an earnings per share (EPS) of $2.88, which represents an increase compared to its EPS of $1.8 in 2024. Exelixis's earnings per share for the quarterly report ending on Mar 31, 2026 was $0.81.

EXEL earnings history

Historical annual and quarterly earnings per share (EPS) data for Exelixis
EPS (TTM)
$3.12
EPS Growth YoY (Quarterly)
42.1%
EPS (Quarterly)
$0.81
EPS Growth (Quarterly)
-11%

The annual EPS in 2025 was $2.88, an increase of 60% from $1.8 in 2024. For the quarter ending Mar 31, 2026, the EPS was $0.81, showing a 42.1% increase from the same quarter last year. The trailing twelve months (TTM) EPS as of March 2026 is $3.12. In 2024, the annual EPS was $1.8, showing an increase of 176.9% from 2023.

EXEL earnings chart

EXEL EPS growth history

Earnings per share growth rates over time
EPS Growth YoY (Quarterly)
42.1%
EPS growth YoY
60%
EPS growth 3Y avg
71.6%
EPS growth 5Y avg
51.6%

Over the last 12 months, Exelixis has registered an EPS growth of 42.1% (YoY, quarterly). Over a three-year span, the company had an average EPS growth of 71.6% per year. Over the last 5 years, the company had an average EPS growth rate of 51.6%.

EXEL Earnings Waterfall

Breakdown of revenue, profit and net income for Exelixis

EXEL Earnings vs Peers

What are the earnings of EXEL compared to its peers
Stock name Price to Earnings EPS grwoth 1Y EPS grwoth 3Y EPS grwoth 5Y
BMY Bristol Myers Squibb Co 16.28 178.7% 5.3% N/A
EXEL Exelixis Inc 17.9 60% 71.6% 51.6%
PFE Pfizer Inc 18.56 -3.5% -37.4% -3.7%
AMGN Amgen Inc 25.84 88.1% 5.6% 2.9%
JNJ Johnson & Johnson 30.13 90.6% 17.7% 14.8%
MRK Merck & Co Inc 36.29 8% 8.4% 21.2%
CRIS Curis Inc N/A 91.6% N/A N/A

All data is based on quarterly TTM periods, unless otherwise specified.